Most Recent Stories
More NewsRocket could launch its medicines sooner, but Intellia is aiming for larger markets.
Its near-term risks are subtle but bigger than their flying stock price might indicate.
Although Rocket Pharmaceuticals lived up to its name on Wednesday due to an encouraging clinical trial development, the big dogs have some questions about RCKT stock.
The late-stage pharmaceutical company said it had reached an agreement with the Food and Drug Administration regarding a phase 2 trial for a Danon disease therapy.
September S&P 500 futures (ESU23) are down -0.02%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.04% this morning as market participants geared up for a key U.S. consumer inflation report...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...